Efficacy of epoetin-alpha administration on improvement of hemoglobin (Hb) values in anemic patients with non-myeloid cancer
Keywords:
epoetin-alpha, hemoglobin, anemia, non-myeloid cancerAbstract
Background: Anemia in cancer patients is a common finding; it is caused by decrease in production or response to erythropoietin as a result of primary disease or complications of treatment. Traditionally, blood transfusion has been the treatment of choice in cancer related anemia; however, potential short- and long-term complications have limited its use. This study was designed to evaluate the efficacy of epoetin-alpha (a form of recombinant human erythropoietin) administration three times weekly on improvement of hemoglobin (Hb) values in patients with non-myeloid cancer suffering from anemia. Methods: In this open labeled, non randomized trial, a total of 60 patients were recruited. For all patients the baseline Hb values were measured. The study started with subcutaneous injection of epoetin-alpha (Eprex) 10,000 U three times weekly and treatment was continued for 12 weeks. Results: Hb level rose at the end of the second week in nearly all patients but the difference was not statistically significant compared to baseline Hb (p =0.37). At the end of the first months, Hb values were significant compared with baseline and the second week (p<0.001 and p= 0.002, respectively). Statistical analysis revealed a significant improvement in Hb levels in the third month compared to baseline (p <0.001), second week (p = 0.002) and first month (p < 0.001). Conclusion: epoetin-alpha improves Hb levels in cancer patients with anemia.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.